The risk for alzheimer disease decreased with increased dosing of BCG. Bladder instillations of bacillus Calmette-Guérin (BCG) in patients with nonmuscle-invasive bladder cancer (NMIBC) are associated ...

Superficial bladder cancer does recur despite bacillus Calmette–Guérin (BCG) instillations—currently the most effective prophylactic therapy. Antifibrinolytic agents seem to enhance the efficacy of ...

A 65-year-old man with a history of T1 high-grade bladder cancer with CIS underwent successful transurethral resection of bladder tumor (TURBT), without residual tumor on second resection. Given his ...

Credit: ImmunityBio. Nogapendekin alfa inbackicept-pmin is an interleukin-15 receptor agonist. The Food and Drug Administration (FDA) has approved Anktiva ® (nogapendekin alfa inbakicept-pmln) with ...

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

The association between allopurinol use and urologic malignancies: A nested case-control study. This is an ASCO Meeting Abstract from the 2020 Genitourinary Cancers Symposium. This abstract does not ...

A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at ...

Aidixi combined with BCG showed 100% clinical complete response rates at three and six months in high-risk NMIBC patients with HER2 expression. Event-free survival at six months was 100% for patients ...

The approval was based on data from a phase 3 trial in adults with BCG-unresponsive, high-risk, NMIBC with CIS with or without papillary tumors following transurethral resection. The Food and Drug ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s largest independent providers of ...